Flector is a drug owned by Ibsa Institut Biochimique Sa. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 13, 2014. Details of Flector's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5607690 | External anti-inflammatory and analgesic plaster preparation |
Apr, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Flector is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Flector's family patents as well as insights into ongoing legal events on those patents.
Flector's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Flector's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 13, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Flector Generics:
There are no approved generic versions for Flector as of now.
How can I launch a generic of Flector before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Flector's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Flector's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Flector -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.013 | 26 Jun, 2015 | 1 | 13 Apr, 2019 | Extinguished |
Alternative Brands for Flector
There are several other brand drugs using the same active ingredient (Diclofenac Epolamine) as Flector. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Ibsa Inst Bio |
|
About Flector
Flector is a drug owned by Ibsa Institut Biochimique Sa. Flector uses Diclofenac Epolamine as an active ingredient. Flector was launched by Ibsa in 2007.
Approval Date:
Flector was approved by FDA for market use on 31 January, 2007.
Active Ingredient:
Flector uses Diclofenac Epolamine as the active ingredient. Check out other Drugs and Companies using Diclofenac Epolamine ingredient
Dosage:
Flector is available in system form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.3% | SYSTEM | Prescription | TOPICAL |